CMS has announced the average basic Part D premium for 2021 will be $30.50. This presents a slight uptick from the 2020 average basic Part D premium when premiums were around $30. Premium savings over the past three years have amounted to $1.9 billion, according to CMS, and savings are due to […]
Latest Stories
Podcast: Will Patients See Lower Rx Prices, from Trump’s Executive Order?
The latest Patients Rising Podcast features Terry and Bob discussing policies such as co-pay accumulators and rebates, while Katy Talento (former lead health advisor to President Trump) breaks down how the recent Executive Orders to lower prescription drug prices will actually impact patients. Hear […]
The Cost Argument: Requiring Masks for COVID-19
Patients Rising, a national nonprofit organization dedicated to providing support and education to people with chronic and life-threatening illnesses, summarizes the "wear a mask" debate in the United States. A natural study out of the University of Iowa evidenced that the implementation of mask […]
New Value & Outcomes Spotlight Editors Take the Helm
New Editors-in-Chief were recently appointed for Value & Outcomes Spotlight. Zeba M. Khan, RPh, PhD and Laura T. Pizzi, PharmD, MPH will steer the editorial direction of the publication and develop engaging content that will resonate with both HEOR expert and nonexpert audiences around the […]
ISPOR Europe 2020 Is Now Virtual | 14-18 November
Virtual ISPOR Europe 2020, “Improving Health: Establishing Incentives and Sharing Value,” will now be held as a completely virtual conference. Content for Virtual ISPOR Europe 2020 will be delivered both synchronously and asynchronously, through live and on-demand sessions released leading up to the […]
ISPOR’s CSO Dr. Lucinda Orsini shares views on use of RWE by regulators and HTAs
In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics and Outcomes Research (ISPOR), she shares her views on navigating the opportunities and challenges of working with RWE. Dr. Orsini sees substantial […]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from 2019 that included RWE studies to highlight how foreign postmarketing data improves understanding of a product’s risk-benefit profile. The products examined […]
A Digital Bridge To Real-Time COVID-19 Data
Several years ago, the Digital Bridge collaborative was formed, consisting of representatives from three key stakeholder communities: public health, the health care delivery system, and electronic health record (EHR) vendors. They concluded that the ubiquitous footprint of electronic health records […]
AMCP Introduces AMCP Collaborate online community to engage in discussions of managed care
AMCP, the organization for managed care pharmacists, today introduced AMCP Collaborate, an online community designed to give members a new platform to engage with each other in discussions impacting managed care pharmacy. AMCP Collaborate will have private communities for the following groups: […]
5 Questions for the New Chair of NICE Sharmila Nebhrajani
S. Nebharajani assumed the role of chair of NICE in May 2020, most recently serving as CEO of Wilton Park, leading the Global Health program looking at issues of AI and data for health systems in Africa, Asia, among other responsibilities. Medscape UK sat down for an interview, exploring […]
